JY231 Injection for the Treatment of Relapsed/Refractory Neurologic Immune Disorders
NCT06797024 is an interventional trial sponsored by Tongji Hospital. As of 18 Nov 2026, it is recruiting participants. It studies JY231 Injection in Autoimmune Diseases of the Nervous System. The registry lists an enrollment of 20 participants at 1 site in 1 country. The registry lists a start date of 28 Feb 2025 and a primary completion date of 31 Dec 2026. One of its registered investigators has a FindMyKOL profile.
Key facts
Registry attributes as recorded on the ClinicalTrials.gov study record.
| Field | Value |
|---|---|
| Registry ID | NCT06797024 |
| Status | Recruiting |
| Study type | Interventional trial |
| Lead sponsor | Tongji Hospital |
| Enrollment | 20 |
| Registered sites | 1 |
| Countries | 1 |
| Conditions | Autoimmune Diseases of the Nervous System |
| Drugs | JY231 Injection |
| Start | 28 Feb 2025 |
| Primary completion | 31 Dec 2026 |
| Study completion | 31 Mar 2027 |
| Last update posted | 31 May 2025 |
Registered summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.
- Chuan Qin
Tongji Hospital
Principal Investigator - Dai-shi Tian, PhD
Tongji Hospital
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Tongji Hospital Affiliated To Tongji Medical College of Huazhong University of Science and Technology
Wuhan, Hubei
Bitao Bu, MDChuan Qin, MDChunrui Li, MDDaishi Tian, MDDi Wang, MDJianfeng Zhou, MDMin Zhang, MDWei Wang, MDRecruiting
Sites by country
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Questions about NCT06797024
Each answer restates registry values shown on this page.
What is NCT06797024?
NCT06797024 is an interventional trial sponsored by Tongji Hospital. It studies JY231 Injection in Autoimmune Diseases of the Nervous System.
Is NCT06797024 recruiting?
As of 18 Nov 2026, it is recruiting participants. 1 of its 1 sites list their own status as recruiting.
Who leads NCT06797024?
The registry names Chuan Qin (principal investigator, Tongji Hospital), Dai-shi Tian, PhD (principal investigator, Tongji Hospital) and Wei Wang, PhD (principal investigator, Tongji Hospital) as overall officials.
Where does NCT06797024 run?
The registry lists 1 site in 1 country. Every site with a stated country is in one country: China.
Which drugs does NCT06797024 study?
The registered drug and biological interventions are JY231 Injection.
When is NCT06797024 expected to complete?
The registry lists a primary completion date of 31 Dec 2026 and a study completion date of 31 Mar 2027. The sponsor last updated the record on 31 May 2025.
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 18 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.